Moderna CEO Stephane Bancel has warned that the novel coronavirus might never disappear and there are high chances of it becoming an endemic disease

The US biotech company, which stunned the world last year by coming up with a vaccine against the disease caused by the new coronavirus in just a few weeks, received approval for its shot from the European Commission on Wednesday

Moderna COVID-19 Vaccine was authorised for distribution and use under emergency use on December 18; eleven members of the committee, which comprises independent health experts, voted in favour of the vaccine and 0 members voted against

Moderna COVID-19 Vaccine: 20 million doses will be delivered by the end of December 2020; total 200 million doses have been ordered by the US government to date, says the company

Moderna working with US Centers for Disease Control and Prevention and Operation Warp Speed to prepare distribution of mRNA-1273 if FDA chooses to grant an emergency use authorisation

The twin crises of the pandemic and an uneven, uncertain global recovery dominated the first day of a two-day summit under the chairmanship of Saudi Arabia, which hands off the rotating presidency of the G20 to Italy next month

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose

While the company did not give a clear timeline on the release of data from these trials on Thursday, it has said that early data is expected in the coming weeks

Speaking during The Wall Street Journal's annual Tech Live conference on October 19, Moderna CEO Stephane Bancel said if satisfactory interim results from the study take longer to get, government authorisation of the COVID-19 vaccine may not happen until early next year

Presently, there are around 40 different coronavirus vaccines in various stages of human clinical trials, comprising one being developed by Oxford University and AstraZeneca, which is already in an advanced stage of testing

Coronavirus vaccine update: In India, there are three COVID-19 vaccines under human trials--Bharat Biotech's COVAXIN, Oxford's COVDSHIELD, and Zydus Cadila's ZyCoV-D. Serum Institute has already begun a phase-3 trial of Oxford vaccine candidates at 17 sites

Moderna will not be ready to seek emergency use authorization from the Food and Drug Administration before Nov. 25 at the earliest

Last week, Moderna announced the start of a late-stage trial on 30,000 people to demonstrate that its vaccine is safe and effective, the final hurdle prior to regulatory approval

Both vaccine candidates rely on a new technology that allows for faster development and manufacturing than traditional vaccine production methods but does not have an extensive track record

In April, Moderna had received $483 million from the U.S. federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health

Coronavirus vaccine news: Johnson and Johnson has expedited its trials for the COVID vaccine. The final stage of the trial expected to begin in September has been pushed up to the second half of July

Coronavirus vaccine updates: WHO Chief Scientist Dr Soumya Swaminathan said that she expects nearly 2 billion doses of a COVID vaccine by the end of next year

Coronavirus vaccine update: Even though these candidate vaccines have produced encouraging results in early stages, a clearer picture can only emerge when a diverse population gets tested

The biotechnology firm signed agreements with Swiss contract drugmaker Lonza Group AG and the US government to produce massive quantities of its coronavirus vaccine

The company has signed deals with Swiss contract drugmaker Lonza Group AG and the US government to produce massive quantities of its vaccine